Assessment of Staging and Resectability
Based on the NCCN guidelines, I would classify this patient’s pancreatic ductal adenocarcinoma as Locally Advanced (Unresectable).
My primary reason for this classification is the degree of blood vessel involvement shown on his CT scan. The tumor wraps around the superior mesenteric artery by 200 degrees. In my clinical assessment, any tumor contacting a major artery by more than 180 degrees is considered to encase the vessel. While his superior mesenteric vein has only 90 degrees of contact—which would otherwise be manageable—the arterial encasement dictates the overall stage.
I do not recommend upfront surgery because attempting to remove a tumor that completely encases a major artery almost always leaves microscopic cancer cells behind, resulting in a positive surgical margin (R1 or R2 resection). Furthermore, operating under these conditions carries a high risk of life-threatening bleeding without improving long-term survival. I recommend starting with systemic chemotherapy as a biological test of time, allowing us to control microscopic disease and evaluate tumor stability before considering high-risk surgical options.
Approach to Pancreatic Exocrine Insufficiency (PERT)
Because the tumor blocks the pancreatic head, digestive enzymes cannot reach the intestine. This explains his classic symptoms of exocrine insufficiency, including pale, floating, bulky stools (steatorrhea) and progressive weight loss despite a good appetite.
I would prescribe enteric-coated Pancreatic Enzyme Replacement Therapy (PERT), such as Creon. My starting dose would be 50,000 to 75,000 USP units of lipase with each main meal, and 25,000 to 50,000 units with snacks.
When counseling the patient, I would emphasize that capsules must be taken during meals—split between the first bite and mid-meal—so the enzymes mix thoroughly with food. I will advise him to swallow them whole with water, as chewing or crushing them destroys the protective enteric coating and can irritate the mouth. I would also prescribe a daily Proton Pump Inhibitor (such as Omeprazole 20–40 mg) to reduce stomach acid, which stops the enzymes from breaking down too early.
Given the cost and supply challenges of PERT in our local setting, I would counsel him to prioritize taking doses with high-fat or protein-rich main meals if financial constraints require rationing.
Recommendation for Systemic Chemotherapy
I recommend Gemcitabine plus Nab-Paclitaxel for this patient over FOLFIRINOX.
Although his bilirubin dropped significantly to 2.5 mg/dL after biliary drainage via ERCP, it has not returned to a normal range (\le 1.5\text{ mg/dL}). FOLFIRINOX requires normal bilirubin clearance; administering it with elevated bilirubin significantly increases the risk of severe liver toxicity and neutropenia due to impaired irinotecan clearance. Gemcitabine combined with nab-paclitaxel can be safely administered at a bilirubin level of 2.5 mg/dL with minimal adjustment.
Logistically, FOLFIRINOX requires a central venous access port and a continuous 46-hour ambulatory infusion pump, which creates maintenance challenges in an outpatient setting. Gemcitabine plus nab-paclitaxel is given as a straightforward outpatient intravenous infusion on Days 1, 8, and 15 of a 28-day cycle. Given his recent jaundice and weight loss, this regimen offers effective disease control with a lower risk of severe infection and gastrointestinal complications.
Pain Management Strategy
Pancreatic cancer pain is caused by direct tumor pressure and infiltration into the retroperitoneal nerve supply behind the stomach. I would approach his pain management by combining a structured WHO Analgesic Ladder progression with targeted nerve blocks.
I would step up his oral medications directly to strong oral opioids, using immediate-release Morphine titrated for pain spikes, before transitioning to a sustained-release formulation once daily requirements are clear. I would also add an adjuvant agent like Gabapentin or Pregabalin to target the burning back pain caused by retroperitoneal nerve involvement. I will co-prescribe a daily laxative (such as Bisacodyl and Lactulose) from day one to prevent opioid-induced constipation.
Finally, I strongly recommend an early referral for Celiac Plexus Neurolysis (CPN) under endoscopic ultrasound (EUS) or CT guidance. By injecting absolute alcohol around the celiac ganglion, we can permanently block pain signals from the upper abdomen. Performing this procedure early will help lower his overall pain scores, reduce the need for escalating opioid doses, and minimize opioid side effects like sedation and severe constipation.
Key Clinical References
- NCCN Guidelines for Pancreatic Adenocarcinoma: Tempero, M. A., et al. (2023). Pancreatic Adenocarcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network.
- PERT in Pancreatic Cancer: Phillips, M. E., et al. (2021). Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterology.
- Chemotherapy Regimens & Bilirubin Thresholds: Von Hoff, D. D., et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine. / Conroy, T., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine.
- Celiac Plexus Neurolysis: Wyse, J. M., et al. (2011). Early endoscopic ultrasound-guided celiac plexus neurolysis compares favorably to standard pain management in unresectable pancreatic cancer. American Journal of Gastroenterology.